Nitric oxide bioavailability (NO bioavailability)

Nitric oxide (NO) bioavailability refers to the net amount of bioactive nitric oxide available to tissues to perform its physiological signaling functions (PMID: 19249530). It is determined by the balance between NO production, primarily by endothelial nitric oxide synthase (eNOS), and its removal by scavenging molecules or reactive oxygen species like superoxide (PMID: 11334432). In the cardiovascular system, NO is a critical regulator of vascular tone, inhibiting platelet aggregation and preventing leukocyte adhesion to the endothelium (StatPearls: Nitric Oxide). Reduced NO bioavailability is a hallmark of endothelial dysfunction and is strongly associated with the pathogenesis of hypertension, atherosclerosis, and diabetes (PMID: 21835287). Therapeutic strategies to improve NO bioavailability include the use of organic nitrates, phosphodiesterase inhibitors, and soluble guanylate cyclase stimulators, which aim to restore normal vascular signaling (PubChem: Nitric Oxide). Additionally, lifestyle modifications and drugs like statins or ACE inhibitors can enhance eNOS activity or reduce oxidative stress, thereby preserving NO levels (PMID: 15142751). Monitoring NO bioavailability often involves measuring flow-mediated dilation or plasma levels of nitrite and nitrate (PMID: 15653931). Overall, maintaining adequate NO bioavailability is essential for vascular health and the prevention of systemic inflammatory conditions.

Other names

Nitric oxide availabilityBioactive nitric oxideEndothelial nitric oxide levels

Drugs enhance nitric oxide bioavailability through several mechanisms: providing exogenous NO (nitrates), increasing endogenous synthesis via nitric oxide synthase (NOS) activation, reducing NO scavenging by reactive oxygen species (antioxidants), or potentiating downstream signaling through soluble guanylate cyclase (sGC) stimulation or phosphodiesterase-5 (PDE5) inhibition (PMID: 21835287, 19249530).